At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Pembrolizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Pembrolizumab With Cisplatin and Gemcitabine Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab, Gemcitabine, and 1 other intervention for Ovarian Cancer. Completed, enrolled 21 participants across 1 site.
Detailed Summary
To evaluate the efficacy and safety of anti-PD-1 antibody MK-3475 (pembrolizumab) in combination with gemcitabine and cisplatin chemotherapy in women with recurrent platinum-resistant ovarian cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartFeb 2016
Primary CompletionMay 2019
Study CompletionMar 2022
TodayJul 2026
First PostedNov 20, 2015
Enrollment StartFeb 8, 2016
Primary CompletionMay 17, 2019
Study CompletionMar 7, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 10.6 years ago
Interventions
Pembrolizumabdrug
Pembrolizumab IV solution
Gemcitabinedrug
Gemcitabine IV solution
Cisplatindrug
Cisplatin IV solution